Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Castagnetti

Showing results (111-120 of 158) with videos related to

Pageof 16
Sort By:
Blood|June 25, 2013
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domainSimona Soverini, Caterina De Benedittis, K Machova Polakova, et al.
Blood|June 14, 2012
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysisSimona Luatti, Fausto Castagnetti, Giulia Marzocchi, et al.
International Journal of Cardiology|April 29, 2019
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary preventionGiovanni Caocci, Olga Mulas, Massimiliano Bonifacio, et al.
Blood|May 17, 2013
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemiaDomenico Russo, Giovanni Martinelli, Michele Malagola, et al.
Cancer Genetics and Cytogenetics|May 18, 2010
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implicationsAlfonso Zaccaria, Nicoletta Testoni, Anna Maria Valenti, et al.
Blood|March 7, 2009
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet StudyMichele Baccarani, Gianantonio Rosti, Fausto Castagnetti, et al.
Annals of Hematology|April 18, 2026
Age and gender effects on molecular responses in chronic myeloid leukemia patients by first-line treatment: an Italian CML network cohort studyMassimo Breccia, Valentina Giai, Tiziana Rosso, et al.
Haematologica|April 7, 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 studyGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Haematologica|June 3, 2017
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Frontiers in Oncology|March 21, 2022
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML StudyAlessandra Iurlo, Daniele Cattaneo, Silvia Artuso, et al.
Pageof 16

Showing results (111-120 of 158) with videos related to

Sort By:
Pageof 16
Blood|June 25, 2013
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domainSimona Soverini, Caterina De Benedittis, K Machova Polakova, et al.
Blood|June 14, 2012
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysisSimona Luatti, Fausto Castagnetti, Giulia Marzocchi, et al.
International Journal of Cardiology|April 29, 2019
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary preventionGiovanni Caocci, Olga Mulas, Massimiliano Bonifacio, et al.
Blood|May 17, 2013
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemiaDomenico Russo, Giovanni Martinelli, Michele Malagola, et al.
Cancer Genetics and Cytogenetics|May 18, 2010
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implicationsAlfonso Zaccaria, Nicoletta Testoni, Anna Maria Valenti, et al.
Blood|March 7, 2009
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet StudyMichele Baccarani, Gianantonio Rosti, Fausto Castagnetti, et al.
Annals of Hematology|April 18, 2026
Age and gender effects on molecular responses in chronic myeloid leukemia patients by first-line treatment: an Italian CML network cohort studyMassimo Breccia, Valentina Giai, Tiziana Rosso, et al.
Haematologica|April 7, 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 studyGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Haematologica|June 3, 2017
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Frontiers in Oncology|March 21, 2022
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML StudyAlessandra Iurlo, Daniele Cattaneo, Silvia Artuso, et al.
Pageof 16